Sun Pharma to conduct clinical trial of pancreatitis drug in COVID-19 patients

Shares of Sun Pharma rose 5 percent intraday on Friday after receiving approval from the Indian drug regulator for clinical trial of its drug on COVID-19 patients.

Reuters May 31, 2020 20:01:29 IST
Sun Pharma to conduct clinical trial of pancreatitis drug in COVID-19 patients

Bengaluru: Drugmaker Sun Pharmaceutical Industries Ltd said on Friday that it received Indian regulatory approval to start clinical trials of pancreatitis drug nafamostat mesilate in COVID-19 patients.

"Nafamostat (has been) identified as a potential candidate for COVID-19 patients by scientists at University of Tokyo and Leibniz Institute for Primate Research, Germany," the company said in a statement.

Click here to follow LIVE updates on coronavirus outbreak

The University of Tokyo had announced plans for a trial of nafamostat and camostat mesilate, a related drug, starting as early as April 2020.

Shares of Sun Pharma rose 5 percent intraday on Friday after receiving approval from the Indian drug regulator for clinical trial of its drug on COVID-19 patients.

Updated Date:

Find latest and upcoming tech gadgets online on Tech2 Gadgets. Get technology news, gadgets reviews & ratings. Popular gadgets including laptop, tablet and mobile specifications, features, prices, comparison.

also read

'Protection is must': Experts urge public to strictly follow COVID-19 guidelines as India reports over 5 lakh cases
India

'Protection is must': Experts urge public to strictly follow COVID-19 guidelines as India reports over 5 lakh cases

Medical experts told ANI that the rise in cases in India is still not high as compared to other countries but said that people should follow COVID-19 guidelines such as wearing face masks. Dr Suresh Kumar, Medical Director, Lok Nayak Jai Prakash (LNJP) Hospital said that urban mobility is a likely cause in the spike in cases.

As world waits for COVID-19 vaccine, India must use time to build robust immunisation plan, delivery system for last-mile reach
India

As world waits for COVID-19 vaccine, India must use time to build robust immunisation plan, delivery system for last-mile reach

Right from selecting the strategy for delivery of COVID-19 vaccine to recruiting a large volunteer staff, every tool must be analysed from the perspective of India’s unique public health system and its capabilities

India reports 14,821 new COVID-19 patients, 445 deaths in past 24 hours; total case count crosses 4.2 lakh with toll now at 13,699
India

India reports 14,821 new COVID-19 patients, 445 deaths in past 24 hours; total case count crosses 4.2 lakh with toll now at 13,699

India on Monday added 14,821 new COVID-19 cases pushing the infection tally to 4,25,282, while the death toll rose to 13,699 with 445 new fatalities, according to Union Health Ministry data.